Core Insights - The BioMedWire Podcast features an interview with Panna Sharma, CEO of Lantern Pharma, focusing on the company's AI-driven approach to developing targeted cancer therapies [2][4] - Lantern Pharma's RADR® AI platform aims to address the high costs and long timelines associated with cancer drug development, which currently averages $250 billion annually and takes 10 to 12 years with a 93% failure rate [4][7] - The company is currently conducting three clinical trials for potential drug candidates, which could each be valued at several billion USD [2][4] Company Overview - Lantern Pharma is positioned as an AI-first company dedicated to creating innovative cancer medicines, leveraging machine learning and big data to enhance drug discovery [4][7] - The company has a pipeline of clinical-stage drug candidates targeting novel cancer mechanisms, with a focus on precision oncology, particularly in brain cancers [5][7] - Recent developments include the addition of a new board member from a recently acquired brain cancer company, indicating a strategic move to strengthen its expertise in this area [5] Market Outlook - Sharma anticipates significant advancements in treating difficult cancers, especially brain cancers, over the next five to seven years, marking a new era in precision neuro-oncology [5] - The recent approval of three brain cancer drugs after a long drought of 17 years highlights a shift in the market and potential opportunities for innovation in cancer treatment [5]